Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-EDTMP plus docetaxel and prednisolone versus docetaxel and prednisolone for pain relief in prostate cancer with bone metastases
IRCT20190303042892N2Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of docetaxel and prednisolone in prostate cancer (PCa) (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Patient pain evaluation. Started Apr 2021; status: completed.
02
Drugs
docetaxelprednisolone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on IRCT20190303042892N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190303042892N2.